As breast cancer therapy improves survival rates, the impact of long-term treatment complications like lymphedema becomes more significant. Breast cancer-related lymphedema (BCRL) can have quality of life and economic implications, with treatment costs ranging from $14,877 to $23,167 over two years. Early detection of BCRL is crucial to prevent progression to chronic lymphedema. Bioimpedance spectroscopy (BIS) is a key tool for early detection and management of lymphedema by measuring fluid levels and tissue composition. Strategies for effective BCRL management include customized exercise programs, compression garments, advanced imaging techniques, and digital health platforms for education and monitoring. Embracing comprehensive management strategies can improve outcomes for individuals at risk or affected by BCRL.
Source link
Redefining Survivorship: Proactive Strategies for Preventing Chronic Breast Cancer-Related Lymphedema
